Blue Note leukaemia DTx gets FDA breakthrough tagA prescription digital therapeutic (DTx) for leukaemia patients developed by Blue Note Therapeutics has been awarded breakthrough device Share XBlue Note leukaemia DTx gets FDA breakthrough taghttps://pharmaphorum.com/news/blue-note-leukaemia-dtx-gets-fda-breakthrough-tag/
BMS cuts $3.15bn deal with Century for cancer cell therapiesBristol-Myers Squibb chief executive Giovanni Caforio has promised to invest in the company’s pipeline at the virtual JP Share XBMS cuts $3.15bn deal with Century for cancer cell therapieshttps://pharmaphorum.com/news/bms-cuts-3-15bn-deal-with-century-for-cancer-cell-therapies/
ASH: Servier’s Tibsovo poised for first-line used in AMLServier has revealed the full data from its phase 3 trial of Tibsovo as a first-line treatment for Share XASH: Servier’s Tibsovo poised for first-line used in AMLhttps://pharmaphorum.com/news/ash-serviers-tibsovo-poised-for-first-line-used-in-aml/
Kura hit as FDA slaps partial hold on leukaemia trialShare in Kura Oncology have come under pressure after a patient death in a clinical trial of the Share XKura hit as FDA slaps partial hold on leukaemia trialhttps://pharmaphorum.com/news/kura-hit-as-fda-slaps-partial-hold-on-leukaemia-trial/
Gamble by Takeda on unproven cancer mechanism draws a blankTakeda says a phase 3 trial of its cancer candidate pevonedistat – a class-leading NEDD8-activating enzyme inhibitor – Share XGamble by Takeda on unproven cancer mechanism draws a blankhttps://pharmaphorum.com/news/takeda-gamble-on-unproven-cancer-mechanism-draws-a-blank/
Servier gets a win for cancer drug Tibsovo, bought in $1.8bn Agios dealJust three months after completing its $1.8 billion takeover of Agios’ oncology pipeline, Servier has reported positive results Share XServier gets a win for cancer drug Tibsovo, bought in $1.8bn Agios dealhttps://pharmaphorum.com/news/servier-gets-a-win-for-cancer-drug-tibsovo-bought-in-1-8bn-agios-deal/
EU okays BMS’ azacitidine pill for first-line maintenance of AMLBristol-Myers Squibb has been granted EU approval for Onureg (azacitidine), a tablet form of an intravenous drug that Share XEU okays BMS’ azacitidine pill for first-line maintenance of AMLhttps://pharmaphorum.com/news/eu-okays-bms-azacitidine-pill-for-first-line-maintenance-of-aml/
J&J backs out of $1.6bn blood cancer antibody alliance with ArgenxBelgian biotech Argenx has lost its development partner for acute myeloid leukaemia antibody cusatuzumab, after Johnson & Johnson Share XJ&J backs out of $1.6bn blood cancer antibody alliance with Argenxhttps://pharmaphorum.com/news/jj-backs-out-of-1-6bn-blood-cancer-antibody-alliance-with-argenx/
Rubius launches $200m IPO to fund red blood cell therapiesRubius Therapeutics has announced the pricing of its Nasdaq IPO, aiming to raise $200 million towards its novel Share XRubius launches $200m IPO to fund red blood cell therapieshttps://pharmaphorum.com/news/rubius-launches-200m-ipo-for-red-blood-cell-therapies/
